Frederic Chereau has been named president and chief executive officer of Pervasis Therapeutics, Inc. (Cambridge, MA).
Frederic Chereau has been named president and chief executive officer of Pervasis Therapeutics, Inc. (Cambridge, MA). Chereau was formerly the vice president and general manager of Genzyme Cardiovascular (CV), a business unit within Genzyme Corporation. Under Chereau’s leadership, Genzyme CV expanded its cell and gene therapy programs and initiated research and commercial efforts in new markets. He was responsible for launching and commercializing a hypercholesterolemia product (Cholestagel–colesevelam) outside the US and oversaw the company’s late clinical stage gene therapy program in peripheral arterial disease and various earlier-stage programs.
